TOKYO--(BUSINESS WIRE)--Konica Minolta, Inc. (“Konica Minolta”) (TOKYO: 4902) (ISIN: JP3300600008) and Innovation Network Corporation of Japan (“INCJ”) today announced the close of their joint acquisition of Ambry Genetics Corporation (“Ambry”) on October 19, 2017 (JST). Known as a pioneer and thought leader in genetic testing, Ambry is the first laboratory in the world to offer hereditary cancer panels and clinical exome sequencing.
This strategic acquisition was announced on July 6, 2017. Through this acquisition, Konica Minolta and INCJ will accelerate the precision medicine business by creating a new medical platform to improve patients’ quality of life while also saving the healthcare system money.
Ambry chose to partner with Konica Minolta to accelerate the development of new diagnostic tests for many different diseases for patients throughout the world. Together they have the combined resources, technology, and scale to advance biomedical research on a global scale, resulting in better tests for doctors and more precise treatments for their patients.
About Konica Minolta
Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, we create products and digital solutions for the betterment of business and society—today and for generations to come. Across our Business Technologies, Healthcare, and Industrial-facing businesses, we aspire to be an Integral Value Provider that applies the full range of our company’s expertise to offer comprehensive solutions to our customer’s most pressing problems, work with our partners to ensure our solutions are sustainable, anticipate and address tomorrow’s issues, and tailor each solution to meet the unique and specific needs of our valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for our customers, and provides leading-edge service solutions in the IoT era.
Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/.
INCJ was established in July 2009 as a public-private investment company that provides financial, technological and management support for next-generation businesses. INCJ specifically supports those projects that combine technologies and varied expertise across industries and materialize open innovation. INCJ has the capacity to invest up to JPY2 trillion (approx. US$20 billion).
INCJ’s management team is drawn from the private sector with diverse experience in investment, technologies and management. Through its Innovation Network Committee, INCJ assesses investment opportunities that contribute to industrial innovation in Japan in line with criteria set by the government. For more information please see: http://www.incj.co.jp/english/.
About Ambry Genetics
Since 1999, Ambry’s mission has remained focused on understanding disease so cures can come faster. Today, Ambry remains unwavering in its commitment to being tough, innovative, committed to quality and, most of all, focused to do what is right for patient care. For more information on Ambry’s full suite of genetic testing, visit http://www.ambrygen.com.